These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 13000058)

  • 1. Levels of homotypic neutralizing antibody in human poliomyelitis three years after infection.
    WINSSER J; SABIN AB
    J Exp Med; 1952 Nov; 96(5):477-90. PubMed ID: 13000058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody response of patients with poliomyelitis to virus recovered from their own alimentary tract.
    STEIGMAN AJ; SABIN AB
    J Exp Med; 1949 Oct; 90(4):349-72. PubMed ID: 18140667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homotypic complement-fixing antibody in monkeys infected with type 2 poliomyelitis virus by the oral route.
    CASALS J; OLITSKY PK; SABIN AB
    J Exp Med; 1952 Jul; 96(1):55-8. PubMed ID: 14946328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transitory appearance of type 2 neutralizing antibody in patients infected with type 1 poliomyelitis virus.
    SABIN AB
    J Exp Med; 1952 Jul; 96(1):99-106. PubMed ID: 14946332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative studies of the virus-host relationship in chimpanzees after inapparent infection with Coxsackie viruses. I. The virus carrier state and the development of neutralizing antibodies.
    MELNICK JL; KAPLAN AS
    J Exp Med; 1953 Mar; 97(3):367-400. PubMed ID: 13052807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement-fixing antibodies to type 2 (Lansing) poliomyelitis virus in a normal population of a subtropical area.
    GOLDBLUM N; MELNICK JL
    J Exp Med; 1952 Aug; 96(2):175-85. PubMed ID: 14955573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development, persistence, and significance of type 2, poliomyelitis complement-fixing antibody in man.
    CASALS J; OLITSKY PK; SABIN AB
    J Exp Med; 1952 Jul; 96(1):35-53. PubMed ID: 14946327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An epidemic of paralytic poliomyelitis characterized by dual infections with poliomyelitis and Coxsackie viruses.
    MELNICK JL; KAPLAN AS; ZABIN E; CONTRERAS G; LARKUM NW
    J Exp Med; 1951 Dec; 94(6):471-92. PubMed ID: 14897994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A specific complement-fixation test for infection with poliomyelitis virus.
    CASALS J; OLITSKY PK; ANSLOW RO
    J Exp Med; 1951 Aug; 94(2):123-37. PubMed ID: 14861374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological reactions of the Coxsackie viruses. I. The neutralization test; technic and application.
    MELNICK JL; LEDINKO N
    J Exp Med; 1950 Nov; 92(5):463-82. PubMed ID: 14778925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between serum antibodies and subclinical infections with poliomyelitis virus.
    BROWN GC; AINSLIE JD
    J Exp Med; 1951 Mar; 93(3):197-205. PubMed ID: 14824395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. THE FORMATION AND PROPERTIES OF POLIOVIRUS-NEUTRALIZING ANTIBODY. I. 19S AND 7S ANTIBODY FORMATION: DIFFERENCES IN KINETICS AND ANTIGEN DOSE REQUIREMENT FOR INDUCTION.
    SVEHAG SE; MANDEL B
    J Exp Med; 1964 Jan; 119(1):1-19. PubMed ID: 14113113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative neutralizing antibody patterns to Lansing (type 2) poliomyelitis virus in different populations.
    PAUL JR; MELNICK JL; RIORDAN JT
    Am J Hyg; 1952 Nov; 56(3):232-51. PubMed ID: 12996493
    [No Abstract]   [Full Text] [Related]  

  • 14. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lansing poliomyelitis virus neutralizing antibody titers of different types of human serum.
    LEVINSON SO; MILZER A; WOLF AM
    Ill Med J; 1951 Oct; 100(4):238-40. PubMed ID: 14873311
    [No Abstract]   [Full Text] [Related]  

  • 16. Ohio strains of a virus pathogenic for infant mice, Coxsackie group; simultaneous occurrence with poliomyelitis virus in patients with summer grippe.
    MELNICK JL; LEDINKO N
    J Exp Med; 1950 Feb; 91(2):185-95. PubMed ID: 15409906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibody response variation against dengue 3 strains.
    Alvarez M; Pavon-Oro A; Rodriguez-Roche R; Bernardo L; Morier L; Sanchez L; Alvarez AM; Guzmán MG
    J Med Virol; 2008 Oct; 80(10):1783-9. PubMed ID: 18712848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of antibody in experimental poliomyelitis; reproducibility of endpoint in a mouse neutralization test with Lansing poliomyelitis virus.
    MORGAN IM
    Am J Hyg; 1947 May; 45(3):372-8. PubMed ID: 20240022
    [No Abstract]   [Full Text] [Related]  

  • 19. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
    Ruppach H; Nara P; Raudonat I; Elanjikal Z; Rübsamen-Waigmann H; Dietrich U
    J Virol; 2000 Jun; 74(12):5403-11. PubMed ID: 10823844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of serum neutralizing antibody response in patients with primary dengue virus type 1 infection].
    Hu D; Li J; Wang D; DI B; Qiu L; Wang Y; Ding X; Che X
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1773-6, 1791. PubMed ID: 23268408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.